Get the Stockscreener App
87.02
1.54%
-1.36
Spdr Biotech Etf stock is traded at $87.02, with a volume of 7.71M.
It is down -1.54% in the last 24 hours and up +3.14% over the past month.
See More
Previous Close:
$88.38
Open:
$87.58
24h Volume:
7.71M
Relative Volume:
0.64
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.09%
1M Performance:
+3.14%
6M Performance:
-2.71%
1Y Performance:
-11.17%
1-Day Range:
$86.70
$87.91
1-Week Range:
$83.02
$88.61
52-Week Range:
$66.66
$105.47
Spdr Biotech Etf Stock (XBI) Company Profile
Name
Spdr Biotech Etf
Sector
Industry
Phone
-
Address
-
Compare XBI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBI
Spdr Biotech Etf
|
87.02 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
307.02 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
623.62 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
626.44 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
242.30 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
554.20 | 124.43B | 0 | 0 | 0 | 0.00 |
Spdr Biotech Etf Stock (XBI) Latest News
Dynamic Advisor Solutions LLC Takes $825,000 Position in SPDR S&P Biotech ETF (NYSEARCA:XBI) - Defense World
3,309 Shares in SPDR S&P Biotech ETF (NYSEARCA:XBI) Bought by Park Avenue Securities LLC - Defense World
SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Purchased by GAMMA Investing LLC - Defense World
Should You Invest in the SPDR S&P Biotech ETF (XBI)? - sharewise
Long Term Trading Analysis for (XBI) - news.stocktradersdaily.com
Should You Invest in the iShares Biotechnology ETF (IBB)? - sharewise
How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks? - The Globe and Mail
(XBI) Trading Advice - news.stocktradersdaily.com
Northern Trust Corp Reduces Position in SPDR S&P Biotech ETF (NYSEARCA:XBI) - Defense World
Hedge Funds Question Market Rally, Build Massive Short WallAmer Sports (NYSE:AS), First Solar (NASDAQ:FSLR) - Benzinga
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Nasdaq
(XBI) Investment Analysis and Advice - news.stocktradersdaily.com
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment - Benzinga
Zacks Investment Ideas feature highlights: Alibaba, JD.com, SPDR S&P Biotech ETF, Merck and Microsoft - TradingView
XBI: Some Tariff Relief Right Now, But Macro Risks Remain In Biotech (NYSEARCA:XBI) - Seeking Alpha
Optimism is Back for Biotech Stocks. This Time, It Could Last. - MSN
MBB Leads With $1.2B Gain as Markets React to UK Trade Deal - TradingView
XBI, EXAS, ALNY, NTRA: Large Outflows Detected at ETF - Nasdaq
(XBI) Investment Analysis - news.stocktradersdaily.com
XBI, Biotech Stocks Retreat: Buy, Hold or Sell? - ETF.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
SPDR S&P Biotech ETF Target of Unusually High Options Trading (NYSEARCA:XBI) - Defense World
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - Yahoo Finance
Optimism Is Back for Biotech Stocks. This Time, It Could Last. - Barron's
Renaissance Technologies LLC Purchases Shares of 5,500 SPDR S&P Biotech ETF (NYSEARCA:XBI) - Defense World
Should You Invest in the VanEck Biotech ETF (BBH)? - Nasdaq
ETFs That Outperform the S&P 500: ARKK, VGT, IWF, XBI - Markets.com
(XBI) On The My Stocks Page - news.stocktradersdaily.com
Alliancebernstein L.P. Makes New Investment in SPDR S&P Biotech ETF (NYSEARCA:XBI) - Defense World
6 Best Health Care Funds and ETFs for 2025 | Investing | U.S. News - Money/ US News
O Shaughnessy Asset Management LLC Has $65,000 Position in SPDR S&P Biotech ETF (NYSEARCA:XBI) - Defense World
Biotech stocks to own amid market volatility – Piper Sandler (XBI:NYSEARCA) - Seeking Alpha
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - Yahoo Finance
How the (XBI) price action is used to our Advantage - news.stocktradersdaily.com
11 Stocks to Buy After the Biotech Bloodbath - Barron's
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies - Asianet Newsable
Wednesday's ETF Movers: XBI, PICK - Nasdaq
XBI Crosses Critical Technical Indicator - Nasdaq
Analysts at Cantor, formerly headed by Lutnick, call for Kennedy's dismissal - Reuters
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Spdr Biotech Etf Stock (XBI) Financials Data
There is no financial data for Spdr Biotech Etf (XBI). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):